Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report issued on Saturday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Trading Down 3.0 %

NASDAQ EVOK opened at $2.25 on Friday. The company has a market cap of $3.36 million, a P/E ratio of -0.20 and a beta of 0.30. Evoke Pharma has a 1 year low of $2.19 and a 1 year high of $12.32. The company has a fifty day simple moving average of $4.05 and a 200 day simple moving average of $4.57.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24). Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%. The business had revenue of $3.31 million during the quarter, compared to the consensus estimate of $3.08 million.

Institutional Investors Weigh In On Evoke Pharma

A hedge fund recently raised its stake in Evoke Pharma stock. Nantahala Capital Management LLC lifted its position in Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 148,194 shares of the specialty pharmaceutical company’s stock after purchasing an additional 91,945 shares during the quarter. Nantahala Capital Management LLC owned 9.95% of Evoke Pharma worth $655,000 at the end of the most recent reporting period.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.